| . | n . | % . |
|---|---|---|
| Age (years), median [range] | 65 [33–79] | |
| PS | ||
| 0 | 5 | 55.6% |
| 1 | 4 | 44.4% |
| Histology | ||
| Squamous cell carcinoma | 9 | 100.0% |
| Origin | ||
| Oral cavity | 8 | 88.9% |
| Oropharynx | 1 | 11.1% |
| Pathological stage (UICC 8th) | ||
| IVA | 4 | 44.4% |
| IVB | 5 | 55.6% |
| Induction chemotherapy before surgery | ||
| Yes | 7 | 77.8% |
| No | 2 | 22.2% |
| High-risk adverse feature | ||
| Extranodal extension | 2 | 22.2% |
| Positive microscopic margins | 4 | 44.4% |
| Extranodal extension + positive microscopic margins | 3 | 33.3% |
| . | n . | % . |
|---|---|---|
| Age (years), median [range] | 65 [33–79] | |
| PS | ||
| 0 | 5 | 55.6% |
| 1 | 4 | 44.4% |
| Histology | ||
| Squamous cell carcinoma | 9 | 100.0% |
| Origin | ||
| Oral cavity | 8 | 88.9% |
| Oropharynx | 1 | 11.1% |
| Pathological stage (UICC 8th) | ||
| IVA | 4 | 44.4% |
| IVB | 5 | 55.6% |
| Induction chemotherapy before surgery | ||
| Yes | 7 | 77.8% |
| No | 2 | 22.2% |
| High-risk adverse feature | ||
| Extranodal extension | 2 | 22.2% |
| Positive microscopic margins | 4 | 44.4% |
| Extranodal extension + positive microscopic margins | 3 | 33.3% |
PS, performance status; UICC 8th, Union for International Cancer Control 8th edition.
| . | n . | % . |
|---|---|---|
| Age (years), median [range] | 65 [33–79] | |
| PS | ||
| 0 | 5 | 55.6% |
| 1 | 4 | 44.4% |
| Histology | ||
| Squamous cell carcinoma | 9 | 100.0% |
| Origin | ||
| Oral cavity | 8 | 88.9% |
| Oropharynx | 1 | 11.1% |
| Pathological stage (UICC 8th) | ||
| IVA | 4 | 44.4% |
| IVB | 5 | 55.6% |
| Induction chemotherapy before surgery | ||
| Yes | 7 | 77.8% |
| No | 2 | 22.2% |
| High-risk adverse feature | ||
| Extranodal extension | 2 | 22.2% |
| Positive microscopic margins | 4 | 44.4% |
| Extranodal extension + positive microscopic margins | 3 | 33.3% |
| . | n . | % . |
|---|---|---|
| Age (years), median [range] | 65 [33–79] | |
| PS | ||
| 0 | 5 | 55.6% |
| 1 | 4 | 44.4% |
| Histology | ||
| Squamous cell carcinoma | 9 | 100.0% |
| Origin | ||
| Oral cavity | 8 | 88.9% |
| Oropharynx | 1 | 11.1% |
| Pathological stage (UICC 8th) | ||
| IVA | 4 | 44.4% |
| IVB | 5 | 55.6% |
| Induction chemotherapy before surgery | ||
| Yes | 7 | 77.8% |
| No | 2 | 22.2% |
| High-risk adverse feature | ||
| Extranodal extension | 2 | 22.2% |
| Positive microscopic margins | 4 | 44.4% |
| Extranodal extension + positive microscopic margins | 3 | 33.3% |
PS, performance status; UICC 8th, Union for International Cancer Control 8th edition.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
